---
title: "New research on the weight-loss version of semaglutide published: Most weight loss is due to fat reduction, with no impact on muscle function"
description: "Novo Nordisk announced at the 2025 European Association for the Study of Diabetes annual meeting that the STEP UP trial showed an average weight reduction of 21% in subjects receiving high doses of se"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258033080.md"
published_at: "2025-09-19T07:27:34.000Z"
---

# New research on the weight-loss version of semaglutide published: Most weight loss is due to fat reduction, with no impact on muscle function

> Novo Nordisk announced at the 2025 European Association for the Study of Diabetes annual meeting that the STEP UP trial showed an average weight reduction of 21% in subjects receiving high doses of semaglutide treatment, with one-third of subjects experiencing a reduction of over 25%. The study indicated that the weight loss was primarily due to a reduction in body fat, and there were no significant differences in lean body mass and muscle mass changes compared to the placebo group, with muscle function remaining good

Novo Nordisk announced multiple research results at the 2025 European Association for the Study of Diabetes annual meeting. Among them, the STEP UP trial showed that subjects receiving higher doses of semaglutide achieved an average weight reduction of 21% compared to the placebo group, with one-third of subjects experiencing a weight loss of 25% or more. In the STEP UP trial, the weight loss achieved with semaglutide 7.2 mg was primarily due to a reduction in body fat. Subgroup analysis results from the STEP UP trial indicated that there were no significant differences in changes in lean body mass and muscle mass between subjects treated with semaglutide 7.2 mg and the placebo group, and muscle function was also maintained

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| US sugar industry weighs impact from new dietary guidelines regulation | The U.S. sugar industry is facing potential impacts from new dietary guidelines that may reduce domestic sugar demand. S | [Link](https://longbridge.com/en/news/276479104.md) |
| FDA Approves Novo Nordisk Wegovy Pill as First Oral GLP-1 for Weight Management | Novo Nordisk's Wegovy® pill, the first oral GLP-1 receptor agonist for weight management, has been approved by the FDA.  | [Link](https://longbridge.com/en/news/270541194.md) |
| CSPC Pharmaceutical Group Limited Obtains Approval from the U.S. Food and Drug Administration to Conduct Clinical Trials in the U.S | CSPC Pharmaceutical Group Limited has received FDA approval to conduct clinical trials in the U.S. for its GLP-1/GIP rec | [Link](https://longbridge.com/en/news/276050786.md) |
| Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports | Feb 19 (Reuters) - Johnson & Johnsonis preparing a potential sale of the orthopedics unit that it has been planning to s | [Link](https://longbridge.com/en/news/276370994.md) |
| Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound | Novo Nordisk's high-dose version of Wegovy received a positive recommendation from the EU's drug advisory board, potenti | [Link](https://longbridge.com/en/news/269559288.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.